Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation: Prospective Randomized Controlled Trial

A randomized controlled study to compare the efficacy of mirabegron, solifenacin and propevirine for treatment of Lower urinary tract symptoms during intravesical BCG installation

Inclusion Criteria:

• Patients older than age 18 years.
• Able to provide an informed consent.
• Denovo or recurrent cases with intermediate and high risk NMIBC eligible for intravesical BCG immunotherapy.
• Persistent LUTS after intravesical BCG induction.

Exclusion Criteria:

• International Prostate symptom score (IPSS) greater than 20.
• Post-void residual (PVR) volume greater than 50 ml.
• Use of medications for overactive bladder.
• Pelvic surgery within the previous 6 months.
• Hypersensitivity for BCG or any of the above mentioned drugs.
• Tumor recurrence during follow up period.
• Other medical conditions that would be adversely affected by anticholinergics such as history of urinary retention due to BPH(Benign prostatic hyperplasia), constipation and history of narrow angle glaucoma.